Skip to main content
An official website of the United States government
Email

NCI Funding Announcements and Notices for COVID-19

When the pandemic began, NCI issued and revised certain existing grants and cooperative agreements to make funds available to study COVID-19. Open and closed funding notices are listed below.

Open Funding Opportunities
Number Title Release Date Expiration Date
NOT-CA-20-054 Contributing to the Global COVID-19 Crisis Response by Allowing Some NCI-supported Projects to be Redirected to COVID-19-related Research During the Crisis 04/28/2020  
PA-20-135 Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional) 03/10/2020 09/08/2025
Closed Funding Opportunities
Number Title Release Date Expiration Date
NOT-MD-20-025 Notice of Special Interest (NOSI): Simulation Modeling and Systems Science to Address Health Disparities 08/13/2020 05/08/2023
NOT-CA-20-048 Notice of National Cancer Institute (NCI) Participation in PA-18-935 "Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)" 04/03/2020 01/25/2022
NOT-OD-20-129 Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19) in Individuals with Down Syndrome for the INCLUDE Project 06/25/2020 07/13/2021
NOT-CA-21-033 Notice of Special Interest (NOSI): Administrative Supplement Opportunity to Study the Impact of COVID-19 on Global Cancer Prevention and Control 02/03/2021 04/01/2021
RFA-OD-20-018 Emergency Awards: Exosome-based Non-traditional Technologies Towards Multi-Parametric and Integrated Approaches for SARS-CoV-2 (U18 Clinical Trial Not Allowed) 08/06/2020 09/19/2020
RFA-OD-20-014 Emergency Awards: Automatic Detection and Tracing of SARS-CoV-2 (U01 Clinical Trial Not Allowed) 08/06/2020 09/16/2020
NOT-CA-20-082 Notice of Special Interest (NOSI): National Cancer Institute (NCI) Emergency Administrative Supplements for Research and Training Continuity of Postdoctoral Fellows during Coronavirus Disease 2019 (COVID-19) 07/06/2020 08/15/2020
NOT-CA-20-077 Request for Proposals (RFP) Solicitation S20-119: Serological Sciences Network Capacity Building Centers 06/25/2020 07/16/2020
NOT-OD-20-121 Notice of Special Interest (NOSI): Limited Competition for Emergency Competitive Revisions for Community-Engaged Research on COVID-19 Testing among Underserved and/or Vulnerable Populations 06/12/2020 08/07/2020
NOT-OD-20-120 Notice of Special Interest (NOSI): Emergency Competitive Revisions for Community-Engaged Research on COVID-19 Testing among Underserved and/or Vulnerable Populations 06/12/2020 08/07/2020
NOT-OD-20-119 Notice of Special Interest (NOSI): Emergency Competitive Revisions for Social, Ethical, and Behavioral Implications (SEBI) Research on COVID-19 Testing among Underserved and/or Vulnerable Populations 06/12/2020 08/07/2020
RFA-OD-20-013 Emergency Awards: RADx-UP Coordination and Data Collection Center (CDCC) (U24 Clinical Trial Optional) 06/12/2020 08/07/2020
RFA-CA-20-039 Emergency Awards: Research Projects in SARS-CoV-2 Serological Sciences (U01 Clinical Trial Optional) 06/05/2020 07/22/2020
RFA-CA-20-038 Emergency Awards: SARS-CoV-2 Serological Sciences Centers of Excellence (U54 Clinical Trial Optional) 06/05/2020 07/22/2020
NOT-CA-20-066

Notice of Intent to Publish a Funding Opportunity Announcement for Serological Sciences Centers of Excellence

 05/15/2020  
NOT-CA-20-065 Request for Information (RFI): Strategy for Research in Coronavirus Serology Testing and Serological Sciences 05/14/2020 05/26/2020
NOT-CA-20-042 National Cancer Institute Announcement Regarding Availability of Urgent Competitive Revision and Administrative Supplements on Coronavirus Disease 2019 (COVID-19) 04/10/2020 06/26/2020
NOT-CA-20-043 National Cancer Institute Announcement Regarding Availability of Competitive Revision SBIR/STTR Supplements on Coronavirus Disease 2019 (COVID-19) 04/09/2020 06/26/2020
  • Updated:

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “NCI Funding Announcements and Notices for COVID-19 was originally published by the National Cancer Institute.”

Email